Related Experiment Videos

Delivery of paediatric rheumatology care in the UK--the projected shortfall

Helen E Foster1, Mark J Harrison, Clare E Pain

  • 1Musculoskeletal Research Group, Institute of Cellular Medicine, Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. h.e.foster@ncl.ac.uk

Clinical Rheumatology
|December 25, 2010
PubMed

Insights

Many UK adult rheumatologists care for children with rheumatic diseases but lack specific paediatric rheumatology (PRh) training. Upcoming retirements of these specialists will create a significant service gap, necessitating proactive workforce planning.

Area of Science:

  • Rheumatology
  • Paediatric Rheumatology
  • Healthcare Workforce Planning

Background:

  • Adult rheumatologists in the UK have historically managed paediatric rheumatic diseases.
  • Changes in postgraduate training now exclude paediatric rheumatology (PRh) from adult rheumatology curricula.
  • This will leave a gap in care as current specialists retire.

Purpose of the Study:

  • To quantify UK adult rheumatologists currently involved in paediatric rheumatology care.
  • To inform future workforce planning for paediatric rheumatology services.
  • To identify the potential impact of specialist retirement on service provision.

Main Methods:

  • A questionnaire was included in the British Society for Rheumatology annual consultant workforce survey.
  • 584 adult rheumatologists were surveyed, with 403 (69%) responding.
  • Questions focused on involvement in paediatric rheumatology care and retirement timelines.

Main Results:

  • 19% (75/403) of respondents reported managing paediatric rheumatic diseases.
  • A significant proportion of these specialists plan to retire within 5-10 years (18% and 48% respectively).
  • Most provided care in dedicated clinics, but 5% saw children without paediatric input, managing a median of 10 consultations monthly.

Conclusions:

  • Many UK adult rheumatologists contribute to paediatric rheumatology care.
  • Retirement of these specialists, who lack formal PRh training, will lead to a critical shortfall in services.
  • Urgent workforce planning is required to ensure continued clinical provision for children with rheumatic diseases.

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...